Andrew Singleton earned his B.Sc. from the University of Sunderland and his Ph.D. from the University of Newcastle upon Tyne, UK, focusing on the genetic determinants of Alzheimer’s disease and dementia with Lewy bodies. He completed postdoctoral studies at the Mayo Clinic in Florida before joining the National Institute on Aging at the NIH in 2001. Currently, Andrew is an NIH Distinguished Investigator and Director of the Center for Alzheimer’s and Related Dementias at the NIH. He has published over 700 articles on the genetic basis of neurodegenerative disorders. His work aims to identify genetic variants that cause or contribute to these diseases and to understand the molecular mechanisms underlying them.

Professor Tom Foltynie is a Professor of Neurology at UCL Institute of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, London. He specialises in advanced treatments for Parkinson’s disease (PD), including Deep Brain Stimulation (DBS), Apomorphine, and Duodopa. As Chief Investigator, he leads trials on Exenatide, gene therapy, and cell therapy for PD, and oversees the Edmond J. Safra Accelerating Clinical Trials in PD project. His research includes DBS for cognitive issues in PD/DLB and severe Tourette syndrome. He trained at UCL, completed his PhD on PD heterogeneity in Cambridge, and became Professor in 2016.

Prof. Horacio Kaufmann is a distinguished Professor at NYU Grossman School of Medicine, holding positions in Medicine, Neurology, and Pediatrics. He directs the Dysautonomia Center and Division of Autonomic Disorders. His research focuses on autonomic disorders caused by genetic and neurodegenerative conditions, including developing and validating new methods to measure if a potential drug being tested in future clinical trials of patients with MSA is effective.

Prof. Wassilios Meissner, MD PhD, is a Neurologist at the University of Bordeaux and a Visiting Professor at the New Zealand Brain Research Institute. He specializes in Movement Disorders, with a focus on Parkinson’s disease and atypical parkinsonian disorders such as Multiple System Atrophy and Progressive Supranuclear Palsy. Currently at NZBRI, he is studying eye movement control in parkinsonian disorders. His research aims to identify markers of disease progression and develop new treatments for PD and MSA.

Dr. Zane Jaunmuktane is an academic neuropathologist at the Division of Neuropathology and the Queen Square Brain Bank, UCL, dedicated to advancing clinical neuropathology practice and research through cutting-edge technologies.

Her research focuses on neurodegenerative diseases, investigating mechanisms of selective regional and cellular vulnerability and phenotypic diversity. Clinically, she specializes in diagnosing neurodegenerative diseases, as well as molecular neuro-oncology and peripheral nerve biopsy analysis.

Professor Vincenzo Libri is a Consultant in Clinical Pharmacology at the National Hospital for Neurology and Neurosurgery and Director of the NIHR Clinical Research Facility at UCLH. He is also a Professor of Translational Neurology at UCL Institute of Neurology and Director of the Masters in Translational Neuroscience at UCL. His research focuses on neurodegenerative diseases and SARS-COV-2 vaccine trials. Prof. Libri has extensive experience in clinical pharmacology and early phase clinical trials, with numerous publications in prestigious medical journals.

Prof. Schrag is a Professor of Clinical Neurosciences at UCL with a specialist interest in movement disorders, particularly in the clinical aspects of Parkinson’s disease and atypical forms of parkinsonism. Her work on these disorders has been included in a number of national and international guidelines on the diagnosis and management of these disorders.

Professor Kailash Bhatia is a Professor of Clinical Neurology at UCL's Institute of Neurology and an Honorary Consultant Neurologist at the National Hospital for Neurology, Queen Square, London. He trained in neurogenetics and movement disorders at Queen Square after earning his medical and neurology degrees from Bombay University. A Fellow of the Royal College of Physicians and the American Academy of Neurology, his research focuses on movement disorders like Dystonia and Parkinson’s disease. He has over 620 peer-reviewed publications and has edited several books, including the award-winning "Marsden’s Book of Movement Disorders." Professor Bhatia is the founding editor-in-chief of the Movement Disorders Clinical Practice Journal and has served on numerous international committees related to neurology.

Dr. Christopher Kobylecki is a consultant neurologist at the Manchester Centre for Clinical Neurosciences and an honorary senior lecturer at the University of Manchester. He completed a PhD on L-DOPA-induced movements in Parkinson’s disease and has conducted postdoctoral research using PET and MR imaging in parkinsonian syndromes. He leads a specialist Movement Disorder clinic at Salford Royal and oversees the regional service for atypical parkinsonism. Dr. Kobylecki is a member of the Association of British Neurologists' movement disorder advisory group and chairs the Scientific Advisory Panel of the Multiple System Atrophy Trust. His research focuses on motor complications, cognitive and non-motor disorders in Parkinson’s disease, and imaging techniques in dystonia.

Dr Saima Sheikh graduated from University of Leeds Medical School in 2019. After completing her Foundation training in Southampton and Winchester, she undertook Internal Medicine Training in Southampton and Portsmouth. Currently Dr Sheikh is a Senior Research Fellow in Neurology in the Wessex Neurological Centre in Southampton. Here she is Sub-clinical Investigator in a range of clinical trials on Neurodegenerative conditions such as Progressive Supranuclear Palsy, Multiple System Atrophy with Dr Boyd Ghosh as Principal Investigator, as well as Alzheimer’s and Huntington’s Disease with Professor Christopher Kipps as Principal Investigator. She actively participates in the multidiciplinary Atypical Parkinsons Clinic, a specialist regional service run by consultant Neurologists, Dr Boyd Ghosh, and Dr Luke Massey and Clinical coordinator and highly specialised physiotherapist, Jade Donnelly. She is also working as a neurology registrar on the oncall rota.

Qualified in 1996; trained in both General Medicine and Neurology. In my dedicated Uro-Neurology clinics, I see patients across a wide range of neurological disorders that include Multiple sclerosis and related inflammatory disorders, dementias, Parkinson’s Disease and Parkinson's plus syndromes, spinal cord tumour and traumatic disorders such as cauda equina syndrome. A growing number of patients with unexplained bladder, sexual and bowel dysfunction are being referred for evaluating a possible neurological cause, and I lead a dedicated pelvic neurology service that includes pelvic neurophysiology testing evaluating the afferent and efferent sacral somatic innervation, urodynamics testing and close links with Neuroradiology. The department runs a dedicated service for young women presenting with unexplained urinary retention, many of whom ultimately are found to have a primary disorder of sphincter relaxation (Fowler’s syndrome).

Dr. Lotte Kjærsgaard is currently employed at H. Lundbeck A/S as Lead Medical Specialist in Clinical Development - Movement Disorders & Neurodegeneration. She also serves as the Global Trial Lead and Medical Expert for the MASCOT trial.

Dr. Kjærsgaard has 15 years of experience in clinical development, primarily in the field of neurodegeneration. Her expertise extends to neurosurgery and dermatology/immunology, with a strong background in the clinical development of small molecules, topical treatments, and monoclonal antibodies. She holds a medical degree from the University of Copenhagen.

Beatrice T. Yang (M.Sc.Eng) is currently working at H. Lundbeck A/S as Patient Insights Lead Specialist in Global Medical affairs. With 15 years of experience in the pharmaceutical industry, working on various development projects spanning the life cycle, her current role is highly cross-functional and includes strategic research initiatives to support patient focused drug development. Prior to joining the pharmaceutical industry, Beatrice worked as a doctoral research assistant at a clinical research centre.

Caoimhe Morley is a final-year PhD candidate at UCL, currently working under Professor Christos Proukakis in the Department of Clinical and Movement Neurosciences. Caoimhe’s research explores how somatic mutations, which are acquired post-zygotically and result in genetic mosaicism, contribute to the pathology and regional patterns observed in MSA. Using a combination of cytogenetic techniques and targeted long-read sequencing, she hopes to provide greater insight into mutations that are often overlooked in traditional genetic analyses.

Previously, Caoimhe obtained an MSc in Medical Genetics and Genomics from the University of Glasgow, where her research involved analysing RNA sequencing datasets to identify molecular drivers of chemotherapy resistance within the bone marrow microenvironment of acute myeloid leukaemia. She also holds a BSc in Biomedical Sciences (Biochemistry) from the National University of Ireland, Galway, where she conducted research on RNA helicases as regulators of DNA double-stranded break pathways. Caoimhe hopes to apply these insights to her current research on somatic mutations, and ultimately to the broader goal of deepening our understanding of MSA pathogenesis.